Bodycote /£BOY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Bodycote
Bodycote plc (BOY) specializes in heat treatment and thermal processing services aimed at improving the properties of metals and alloys. The company operates within the industrial sector, providing vital services to enhance material performance across multiple industries including aerospace, automotive, and energy. Founded in 1923, Bodycote today provides thermal processing services globally, contributing to the manufacturing processes of various high-performance components.
- Ticker
- £BOY
- Sector
- Industrials
- Primary listing
- LSE
- Employees
- 3,921
- Headquarters
- Macclesfield, United Kingdom
- Website
- www.bodycote.com
Bodycote Metrics
BasicAdvanced
£1.5B
27.27
£0.34
1.35
£0.23
2.51%
Price and volume
Market cap
£1.5B
Beta
1.35
52-week high
£9.68
52-week low
£5.85
Average daily volume
1.5M
Dividend rate
£0.23
Financial strength
Current ratio
1.14
Quick ratio
0.963
Long term debt to equity
0.325
Total debt to equity
0.349
Dividend payout ratio (TTM)
68.04%
Interest coverage (TTM)
17.93%
Profitability
EBITDA (TTM)
174.5
Gross margin (TTM)
14.04%
Net profit margin (TTM)
7.87%
Operating margin (TTM)
14.80%
Effective tax rate (TTM)
25.92%
Revenue per employee (TTM)
£190,000
Management effectiveness
Return on assets (TTM)
6.45%
Return on equity (TTM)
9.35%
Valuation
Price to earnings (TTM)
27.271
Price to revenue (TTM)
2.143
Price to book
2.55
Price to tangible book (TTM)
5.01
Price to free cash flow (TTM)
24.674
Free cash flow yield (TTM)
4.05%
Free cash flow per share (TTM)
0.371
Dividend yield (TTM)
2.51%
Growth
Revenue change (TTM)
1.68%
Earnings per share change (TTM)
114.51%
3-year revenue growth (CAGR)
-2.81%
10-year revenue growth (CAGR)
2.85%
3-year earnings per share growth (CAGR)
-8.41%
10-year earnings per share growth (CAGR)
-0.82%
3-year dividend per share growth (CAGR)
2.56%
10-year dividend per share growth (CAGR)
4.30%
What the Analysts think about Bodycote
Analyst ratings (Buy, Hold, Sell) for Bodycote stock.
Analyst projections of the future price of Bodycote stock.
Bulls say / Bears say
Core organic revenue rose 9.6% in the first half, while core operating profit grew 11% and margins improved. Strong aerospace and defence, industrial gas turbine, medical and semiconductor demand shows that growth is coming from several markets, not just one. (PR Newswire)
Bodycote is investing more than $30 million in Ohio, including a new large-scale hot isostatic pressing vessel, to expand capacity for aerospace and defence work. If demand holds, these higher-specification facilities could support future growth. (Bodycote)
The board-backed cash acquisition gives shareholders a defined route to realise value and makes completion a near-term catalyst. This offers a clearer outcome than relying solely on Bodycote’s longer-term growth plans. (Investegate)
Automotive revenue fell 4% in the first half, with conditions particularly difficult in Western Europe, while industrial markets were broadly flat. Continued weakness in these sizeable end markets could offset growth elsewhere. (PR Newswire)
Management expects revenue growth to slow in the second half as aerospace comparisons become tougher. Normalising staff incentives and costs from new growth projects could also limit margin gains, even though full-year margin improvement remains its forecast. (PR Newswire)
Bodycote’s board warned that structural problems in automotive and industrial markets, alongside macroeconomic uncertainty, create meaningful risk to its medium-term targets. That makes the standalone earnings case less certain if the acquisition does not complete. (Investegate)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.
Bodycote Financial Performance
Revenues and expenses
Bodycote Earnings Performance
Company profitability
Upcoming events
Funds containing Bodycote
AllGBPUSDEUR
Fund name | Fund size | £BOY weighting |
|---|---|---|
Vanguard FTSE 250£VMIG | £569M | 0.50% |
Vanguard FTSE 250£VMID | £1.5B | 0.50% |
iShares FTSE 250£MIDD | £672M | 0.50% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.13% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.13% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.